VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...
Acquisition adds YUPELRI ® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition...
Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78.6% in FRα-positive...
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...
Zymeworks (NASDAQ:ZYME) reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across...
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal...
Barchart Research What to Expect from ZYME Earnings ZYME Generated May 6, 2026 Current Price $27.61 EPS Estimate $$-0.10 Consensus Rating Strong Buy Average Move 3.55% Can Zymeworks Justify Its Valuation...
ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6...